NCT04778787View on ClinicalTrials.gov

Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

PHASE4CompletedINTERVENTIONAL

Enrollment

370

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

August 1, 2022

Study Completion Date

August 1, 2022

Conditions

Congestive Heart Failure

Interventions

DRUG

Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)

Patients will receive dapagliflozin at a dose of 10 mg daily during hospitalization in addition to ongoing therapy

Trial Locations (2)

Unknown

University Clinical Hospital number 1, Moscow

Сity Сlinical Нospital number 7, Moscow

All Listed Sponsors

lead

I.M. Sechenov First Moscow State Medical University

OTHER

NCT04778787 - Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention | Biotech Hunter | Biotech Hunter